Compare CDMOs with autoimmune drug manufacturing expertise for monoclonal antibodies, biosimilars, JAK inhibitors, and other immunomodulators. Filter by modality, scale, and certifications.
Autoimmune disease treatment has been transformed by biologics. Monoclonal antibodies (anti-TNF, anti-IL-6, anti-IL-17, anti-IL-23) dominate the market for rheumatoid arthritis, psoriasis, inflammatory bowel disease, and lupus. The biosimilar wave is driving demand for CDMO capacity as originator patents expire. Meanwhile, oral small molecules (JAK inhibitors, S1P modulators) are gaining ground as convenient alternatives to injectable biologics.
Biologics manufacturing for autoimmune therapies requires commercial-scale mammalian cell culture (CHO cell lines producing monoclonal antibodies at 5-15 g/L titers), robust purification platforms (Protein A chromatography, viral inactivation/removal), and high-volume fill-finish for prefilled syringes and autoinjector devices. Self-administration is the standard, driving demand for patient-friendly delivery devices.
Biosimilar manufacturing adds analytical complexity. Demonstrating biosimilarity requires extensive characterization -- higher-order structure analysis, glycosylation profiling, charge variant analysis, and biological activity assays. CDMOs supporting biosimilar programs need both manufacturing capability and deep analytical services to support the totality-of-evidence regulatory approach.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.